A1 Refereed original research article in a scientific journal
CIP2A Constrains Th17 Differentiation by Modulating STAT3 Signaling
Authors: Mohd Moin Khan, Ubaid Ullah, Meraj H. Khan, Lingjia Kong, Robert Moulder, Tommi Välikangas, Santosh Dilip Bhosale, Elina Komsi, Omid Rasool, Zhi Chen, Laura L. Elo, Jukka Westermarck, Riitta Lahesmaa
Publisher: Cell Press, Elsevier Inc.
Publication year: 2020
Journal: iScience
Journal name in source: iScience
Journal acronym: iScience
Volume: 23
Issue: 3
Number of pages: 46
ISSN: 2589-0042
eISSN: 2589-0042
DOI: https://doi.org/10.1016/j.isci.2020.100947
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/46771919
Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) is an oncogene and a potential cancer therapy target protein. Accordingly, a better understanding of the physiological function of CIP2A, especially in the context of immune cells, is a prerequisite for its exploitation in cancer therapy. Here, we report that CIP2A negatively regulates interleukin (IL)-17 production by Th17 cells in human and mouse. Interestingly, concomitant with increased IL-17 production, CIP2A-deficient Th17 cells had increased strength and duration of STAT3 phosphorylation. We analyzed the interactome of phosphorylated STAT3 in CIP2A-deficient and CIP2A-sufficient Th17 cells and indicated together with genome-wide gene expression profiling, a role of Acylglycerol Kinase (AGK) in the regulation of Th17 differentiation by CIP2A. We demonstrated that CIP2A regulates the strength of the interaction between AGK and STAT3, and thereby modulates STAT3 phosphorylation and expression of IL-17 in Th17 cells.
Downloadable publication This is an electronic reprint of the original article. |  |
